IPO Year: 2025
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $45.00 | Strong Buy | Raymond James |
| 9/3/2025 | $22.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | Buy | TD Cowen | |
| 3/4/2025 | $32.00 | Buy | Stifel |
| 3/4/2025 | $45.00 | Buy | Guggenheim |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
3 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
SCHEDULE 13D/A - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
Fastest customizable press release news feed in the world
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced data presented at the 2025 North American Cystic Fi
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced initiation of the PreciSION CF Phase 2a proof-of-concept (POC) trial evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor
WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that data will be presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington on October 22-25, 2025. Details of the presentation and posters are as follows: Title: Safety, tolerability, and pharmacokinetics of novel NBD1 stabilizers SION-719 and SION-451 from two phase 1 first-in
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO). "We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna," said Mike Cloonan, President and Chief Executive Officer of Sionna. "Caroline's exceptional experience, leadership, and value creation mindset will
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: Cantor Global Healthcare Conference 2025 in New York, NY on Wednesday, September 3rd, 2025, at 1:35 p.m. ET; andMorgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on Monday, September 8th, 2025, at 7:00 a.m. ET.
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that the first subjects have been dosed in a Phase 1 trial evaluating SION-451, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, in proprietary dual combinations with SION-2222 (galicaftor), a transmembrane domain 1 (TMD1)-directed CFTR corrector, and with SION-109, an intracellular loop 4 (ICL4)-directed CFTR co
Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets Initiation of Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care in cystic fibrosis patients is on track for the second half of 2025 with topline data expected in mid-2026 Advancement of Phase 1 healthy volunteer trial of SION-451 in two proprietary dual combinations is on track for the second half of 2025 with topline data expected in mid-2026 Maintained strong cash position with approximately $337.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revo
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Healthcare Conference in Miami, Florida on Wednesday, June 11th 2025 at 8:00 a.m. ET. A live webcast of the presentation will be available the day of the event on the "Events" page within the Investors section of Sionna's website at https://in
Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position following completed upsized IPO, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for c
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Raymond James initiated coverage of Sionna Therapeutics with a rating of Strong Buy and set a new price target of $45.00
RBC Capital Mkts initiated coverage of Sionna Therapeutics with a rating of Sector Perform and set a new price target of $22.00
TD Cowen initiated coverage of Sionna Therapeutics with a rating of Buy
Stifel initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $32.00
Guggenheim initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $45.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
Live Leadership Updates
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO). "We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna," said Mike Cloonan, President and Chief Executive Officer of Sionna. "Caroline's exceptional experience, leadership, and value creation mindset will
Live finance-specific insights
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revo